Description

MabThera (Rituximab)

Generic Name

Rituximab

Brand Name

MabThera®

Drug Class

Monoclonal antibody (anti-CD20 antibody)

Description

MabThera (rituximab) is a chimeric monoclonal antibody that selectively targets the CD20 antigen present on B lymphocytes. By binding to CD20-positive B cells, rituximab promotes their destruction and helps manage diseases in which these cells play a significant role, including certain hematological malignancies and autoimmune disorders. activity in both malignant and autoimmune conditions. Premedication is typically administered to reduce infusion-related reactions. appropriately during treatment. B virus reactivation. /Genentech in various regions worldwide.